Changing Diabetes® in Children (CDiC) is a public-private partnership founded in 2009. Its objective is to contribute to the care of children and young people with type 1 diabetes, living in low- and middle-income countries, until the age of 25. It is based on four pillars: patient education, strengthening the capacity of health professionals, bringing care closer to the people who need it, and access to insulin and monitoring supplies.
Type 1 diabetes is characterized by the destruction of β cells, generally by an autoimmune process leading to a loss of endogenous insulin production. In many cases, pancreatic β-cell destruction occurs at a variable rate and depends on different factors, including genes, age, and ethnicity. It often affects children, adolescents and young adults, but can occur at any age. People with type 1 diabetes must inject insulin every day. Type 1 diabetes cannot be prevented but can be successfully treated.
With 43,300 cases of diabetes in children and adolescents under 19, according to data from the International Diabetes Federation (IDF), Morocco is among the ten countries in the world with the largest number of children and adolescents. adolescents with diabetes. This high prevalence requires deliberate interventions, particularly for vulnerable populations. It is in this sense that Novo Nordisk is in partnership with SMEDIAP, and in collaboration with and the Ministry of Health and Social Protection, to improve the quality of life of children and adolescents living with type 1 diabetes. in Morocco.
We intend to emphasize therapeutic patient education, because we believe that this is essential to the successful management of diabetes. And all young people with type 1 diabetes and their loved ones deserve to benefit from quality care, with structured diabetes education provided by an experienced team of healthcare professionals in pediatric diabetes. By establishing education centers, we bring care closer to the people who need it. The project Changing Diabetes® in Children will also aim to support the establishment of a unified data system for type 1 diabetes, in order to facilitate the coordination of advocacy and care actions between health professionals and other stakeholders.
To be Al RefaiManaging Director of Novo Nordisk in Morocco, announced: ”We are delighted to renew our commitment to defeating diabetes through the project changing Diabetes® in children. This is in line with Novo Nordisk’s social responsibility and I welcome the commitment of our partners, who are working in the same direction, improving the quality of life of young people with type 1 diabetes.
The president of SMEDIAP, Prof. Farida Jennanecommenting on the partnership, said ”As healthcare professionals working in the field of childhood diabetes, we are seeing a gradual increase in the number of cases. These children and their families require specialized care. By establishing education centers and developing educational tools adapted to local realities, we believe that this partnership will improve access to appropriate care for children and adolescents with diabetes, which is linked to the mission of our learned society. ”
The Director General of the Rabat university hospital center Prof. Raouf MOHSINE mentioned: “ Therapeutic education is not an option in the management of type 1 diabetes. It is completely integrated into care and constitutes a major factor in the success of treatment. As the nation’s first teaching hospital, I am honored to see here a center specializing in therapeutic education for children and their families. I want this center to be a reference center for regional health structures.”
Berit BasseAmbassador of Denmark to Morocco declared: “He is pleased to see how Novo Nordisk, in partnership with the Moroccan Society of Pediatric Endocrinology and Diabetology and in collaboration with the Ministry of Health and Social Protection, supports improving access to diabetes care for children and their families through the Changing Diabetes project® in children. I look forward to following the project in the years to come.”
Novo Nordisk will continue to support improved access to diabetes education for patients with type 1 diabetes, through innovative projects and partnerships with diverse stakeholders to drive change to overcome diabetes. diabetes.
